INSILICO (03696) Receives HK$39 Million Milestone Payment from Menarini as Collaborative Project MEN2501 Administers First Dose to Patient

Stock News02-03

INSILICO (03696) announced that the MEN2501 project, which it out-licensed to the Menarini Group, has achieved the first patient dosing in a Phase I clinical trial. According to the collaboration agreement, INSILICO has received a new milestone payment of approximately HK$39 million from Menarini. MEN2501 (previously known as ISM9682) is a highly differentiated small-molecule inhibitor targeting kinesin KIF18A, with preclinical data showing significant inhibitory activity against cancers with chromosomal instability. Previously, as part of a strategic collaboration aimed at accelerating the development of transformative anti-tumor therapies, INSILICO out-licensed the MEN2501 project to Stemline Therapeutics Inc., a wholly-owned subsidiary of the Menarini Group, for a total deal value of $550 million (equivalent to approximately HK$4.29 billion).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129443209?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 08:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129443209","market":"nz","top_or_hot":-1,"title":"INSILICO (03696) Receives HK$39 Million Milestone Payment from Menarini as Collaborative Project MEN2501 Administers First Dose to Patient","media":"Stock News","content":"<p>INSILICO (03696) announced that the MEN2501 project, which it out-licensed to the Menarini Group, has achieved the first patient dosing in a Phase I clinical trial.\nAccording to the collaboration agreement, INSILICO has received a new milestone payment of approximately HK$39 million from Menarini.\nMEN2501 (previously known as ISM9682) is a highly differentiated small-molecule inhibitor targeting kinesin KIF18A, with preclinical data showing significant inhibitory activity against cancers with chromosomal instability.\nPreviously, as part of a strategic collaboration aimed at accelerating the development of transformative anti-tumor therapies, INSILICO out-licensed the MEN2501 project to Stemline Therapeutics Inc., a wholly-owned subsidiary of the Menarini Group, for a total deal value of $550 million (equivalent to approximately HK$4.29 billion).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INSILICO (03696) Receives HK$39 Million Milestone Payment from Menarini as Collaborative Project MEN2501 Administers First Dose to Patient</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINSILICO (03696) Receives HK$39 Million Milestone Payment from Menarini as Collaborative Project MEN2501 Administers First Dose to Patient\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-03 08:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INSILICO (03696) announced that the MEN2501 project, which it out-licensed to the Menarini Group, has achieved the first patient dosing in a Phase I clinical trial.\nAccording to the collaboration agreement, INSILICO has received a new milestone payment of approximately HK$39 million from Menarini.\nMEN2501 (previously known as ISM9682) is a highly differentiated small-molecule inhibitor targeting kinesin KIF18A, with preclinical data showing significant inhibitory activity against cancers with chromosomal instability.\nPreviously, as part of a strategic collaboration aimed at accelerating the development of transformative anti-tumor therapies, INSILICO out-licensed the MEN2501 project to Stemline Therapeutics Inc., a wholly-owned subsidiary of the Menarini Group, for a total deal value of $550 million (equivalent to approximately HK$4.29 billion).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"","article_id":"1129443209","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129443209","pubTimestamp":1770077434,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INSILICO (03696) announced that the MEN2501 project, which it out-licensed to the Menarini Group, has achieved the first patient dosing in a Phase I clinical trial. According to the collaboration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1141":"生命科学工具和服务","03696":"英矽智能"},"translate_title":"英矽智能(03696)获美纳里尼3900万港元里程碑付款合作项目MEN2501为患者施打首剂","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"INSILICO (03696) announced that the MEN2501 project, which it out-licensed to the Menarini Group, has achieved the first patient dosing in a Phase I clinical trial.\nAccording to the collaboration agreement, INSILICO has received a new milestone payment of approximately HK$39 million from Menarini.\nMEN2501 (previously known as ISM9682) is a highly differentiated small-molecule inhibitor targeting kinesin KIF18A, with preclinical data showing significant inhibitory activity against cancers with chromosomal instability.\nPreviously, as part of a strategic collaboration aimed at accelerating the development of transformative anti-tumor therapies, INSILICO out-licensed the MEN2501 project to Stemline Therapeutics Inc., a wholly-owned subsidiary of the Menarini Group, for a total deal value of $550 million (equivalent to approximately HK$4.29 billion).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129443209","isCrawlerRequest":true}